Socialiya - Entertainment. Knowledge. Community.
Revolution beats expectations | ApexOnco - Clinical Trials news and analysis

Revolution Medicines has just toplined the phase 3 Rasolute-302 trial in second-line pancreatic canc...

BUSINESS NEWS April 13, 2026

Revolution beats expectations | ApexOnco - Clinical Trials news and analysis

Revolution Medicines has just toplined the phase 3 Rasolute-302 trial in second-line pancreatic cancer, but it's already calling the results transformative.

16 views 0 likes 0 comments
Share:
Revolution Medicines has just toplined the phase 3 Rasolute-302 trial in second-line pancreatic cancer, but it's already calling the results transformative.

Author: Oncology Pipeline

Read Original Article

Related News

Advertisement
socialiya
Advertisement
APNA POS
Advertisement

Top Categories

Advertisement
APNA POS
Advertisement
APNA POS
Advertisement
APNA POS
Advertisement
socialiya